Table II.
Combined survival analysis of the CXCR subunits in patients with early-stage pancreatic ductal adenocarcinoma.
| OS | DFS | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Variables | MST | P-value | HR crude (95% CI) | P-value | HR adjusted (95% CI)a | P-value | MRT | P-value | HR crude (95% CI) | P-value | HR adjusted (95% CI) a | P-value |
| CXCR3+4+6 | 0.007 | 0.007 | ||||||||||
| All low | 393 | Ref. | 0.011 | Ref. | 0.022 | 593 | Ref. | 0.013 | Ref. | 0.018 | ||
| 1 high | 458 | 0.84 (0.44-1.62) | 0.609 | 0.89 (0.43-1.83) | 0.751 | 291 | 3.03 (1.07-8.57) | 0.037 | 3.75 (1.15-12.18) | 0.028 | ||
| 2 high | 467 | 0.72 (0.35-1.46) | 0.360 | 0.69 (0.32-1.49) | 0.346 | 486 | 1.45 (0.46-4.54) | 0.527 | 1.05 (0.30-3.63) | 0.937 | ||
| All high | 913 | 0.29 (0.13-0.64) | 0.002 | 0.25 (0.10-0.65) | 0.004 | 872 | 0.75 (0.24-2.35) | 0.623 | 0.76 (0.19-3.05) | 0.696 | ||
| CXCR2+6 | 0.013 | 0.020 | ||||||||||
| Low/low | 381 | Ref. | 0.017 | Ref. | 0.087 | 439 | Ref. | 0.030 | Ref. | 0.057 | ||
| Low/high | 603 | 0.49 (0.24-0.99) | 0.048 | 0.84 (0.37-1.92) | 0.683 | 620 | 0.62 (0.24-1.61) | 0.324 | 1.38 (0.43-4.37) | 0.589 | ||
| High/low | 614 | 0.66 (0.34-1.28) | 0.219 | 1.08 (0.51-2.27) | 0.842 | NA | 0.52 (0.19-1.48) | 0.222 | 0.46 (0.14-1.51) | 0.199 | ||
| High/high | 596 | 0.36 (0.19-0.69) | 0.002 | 0.44 (0.22-0.91) | 0.026 | 872 | 0.25 (0.10-0.63) | 0.003 | 0.29 (0.10-0.85) | 0.024 | ||
a
Adjusted for pathological T and N stage, histological grade, radical resection and targeted molecular therapy. CXCR, C-X-C motif chemokine receptor; OS, overall survival time; DFS, disease-free survival time; MST, median survival time; MRT, median disease-free survival time; HR, hazard ratio; CI, confidence interval; NA, not available; Ref., reference.